Stratos Wealth Advisors LLC Makes New 2.02 Million Investment in Catalyst Pharmaceuticals, Inc.
| CPRX Stock | USD 22.22 0.49 2.25% |
Slightly above 55% of Catalyst Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Catalyst Pharmaceuticals stock suggests that some investors are interested at this time. Catalyst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Catalyst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Stratos Wealth Advisors LLC purchased a new position in Catalyst Pharmaceuticals, Inc. in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 83,475 shares of the biopharmaceutical companys stock, valued at approximately 2,024,000. Stratos Wealth Advisors LLC owned approximately 0.07 percent
Read at thelincolnianonline.com
 |
Catalyst Pharmaceuticals Fundamental Analysis
We analyze Catalyst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Catalyst Pharmaceuticals is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Catalyst Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Catalyst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Catalyst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Catalyst Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Catalyst Pharmaceuticals Related Equities
| FOLD | Amicus Therapeutics | 8.07 | ||||
| VKTX | Viking Therapeutics | 3.98 | ||||
| MDGL | Madrigal Pharmaceuticals | 3.29 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.76 | ||||
| DVAX | Dynavax Technologies | 2.58 | ||||
| EXEL | Exelixis | 1.77 | ||||
| VSTM | Verastem | 1.15 | ||||
| TLPH | Talphera | 2.50 | ||||
| AXSM | Axsome Therapeutics | 2.77 |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.